UBS AM’s Hemab Therapeutics COAG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$305K Buy
+9,900
New +$435K ﹤0.01% 2918

Other funds holding COAG

UBS AM's COAG Position: Q3 2026 in Review

UBS AM opened a new position in Hemab Therapeutics (COAG) in Q3 2026: 9,900 shares worth $305K. The stake represents ﹤0.01% of the portfolio and ranks #2918 among its holdings.

87 funds tracked by Wall St. Rank hold COAG as of Q3 2026.

  • UBS AM held 9,900 shares of Hemab Therapeutics worth $305K as of Q3 2026.
  • Hemab Therapeutics was a new UBS AM position in Q3 2026.
  • Hemab Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #2918 holding.
  • 87 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.